Strepto formulations negotiated at a rate of 20%

The NHIS sticks to 20% or more and pharmaceuticals are less than 20%

The pharmaceutical industry has low drug prices, so if the recovery rate is more than 20%, there is no margin left Based on the results of the clinical re-evaluation of the anti-inflammatory enzyme drugs Streptokinase and Streptodornase, the NHIS and pharmaceutical companies, which have started negotiations to recover their salaries, are reportedly showing differences in their positions over the recovery rate.

 

While the NHIS requires more than 20% of the recovery rate, pharmaceutical companies say they can never agree on more than 20%.

 

The return rate of 20% is the rate agreed upon in the negotiation for the return of the brain function improvement drug Choline alfoscerate.

 

According to the industry on the 3rd, the NHIS began negotiations with pharmaceutical companies until the 14th as the HIRA decided to suspend the re-evaluation of benefit adequacy for one year only for items that agreed to be recovered according to the results of clinical re-evaluation.

 

It is said that data has already come and gone along with face-to-face negotiations.

 

The key to negotiations is the rate of return and the period of return.

 

However, it is known that it is not easy to reach an agreement due to significant differences in the recovery rate.

 

The NHIS is said to have offered a higher amount as a baseline for the 20% return rate agreed with Choline alfoscerate pharmaceutical companies in 2021.

 

However, pharmaceutical companies say they can never accept more than 20%.

 

An industry official said, "Streptokinase and Streptodornase have nothing left from the cost if the return rate exceeds 20% because the upper limit is cheap." The upper limit of Streptokinase and Streptodornase is 58 to 70 won, which is not comparable to the 500 won Choline Alfocerate.

 

However, the NHIS is said to be unable to lower the recovery rate as the recovery period is expected to be short as the results of the clinical re-evaluation of the drug are scheduled for next year.

 

In fact, the clinical re-evaluation of Choline alfoscerate was launched last year, and considerable time is left until 2025.

 

In comparison, Streptokinase and Streptodornase are likely not to have a long recovery period like Choline alfoscerate as they have been confirmed to be submitted as a result of clinical re-evaluation next year.

 

However, the recovery period may vary depending on how the NHIS and the pharmaceutical company agree on the timing of the recovery.

 

It is unclear whether an agreement will be reached by the end of the negotiations on the 14th because the gap between the two sides is significant in the recovery rate.

 

If the agreement fails, the Ministry of Health and Welfare is expected to consider whether to order renegotiation or reflect it in the results of salary adequacy.

 

For now, the Ministry of Health and Welfare plans to reflect the results of the re-evaluation of benefit adequacy in the list.